<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Randomized trials for total body or hemibody irradiation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Randomized trials for total body or hemibody irradiation</h1>
<div class="graphic"><div class="figure"><div class="ttl">Randomized trials for total body or hemibody irradiation</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1">Reference </td> <td class="subtitle1">Number of patients </td> <td class="subtitle1">Radiotherapy </td> <td class="subtitle1">Antiemetic </td> <td class="subtitle1">Complete response (percent) </td> <td class="subtitle1">Results </td> </tr> <tr> <td rowspan="2">Tiley<sup>1</sup> </td> <td rowspan="2">20 </td> <td rowspan="2">10.5 Gy (TBI, single fraction) </td> <td>OND (8 mg IV)</td> <td>90*</td> <td rowspan="2">OND better than placebo </td> </tr> <tr> <td>Placebo</td> <td>50*</td> </tr> <tr> <td rowspan="2">Spitzer<sup>2</sup> </td> <td rowspan="2">20 </td> <td rowspan="2">TBI: 13.2 Gy in 11 fractions over 4 days </td> <td>OND (8 mg x 3/day PO)</td> <td>50</td> <td rowspan="2">OND better than placebo </td> </tr> <tr> <td>Placebo</td> <td>0</td> </tr> <tr> <td rowspan="2">Prentice<sup>3</sup> </td> <td rowspan="2">30 </td> <td rowspan="2">7.5 Gy (TBI, single fraction) </td> <td>GRAN (3 mg IV)</td> <td>53</td> <td rowspan="2">GRAN better than MTC + DEX + LOR </td> </tr> <tr> <td>MCP (20 mg IV) + DEX (6 mg/m2 IV) + LOR (2 mg IV)</td> <td>13</td> </tr> <tr> <td rowspan="2">Huang<sup>4</sup> </td> <td rowspan="2">116 </td> <td rowspan="2">7 to 7.7 Gy (TBI, single fraction) </td> <td>OND (8 mg) + DEX (10 mg)</td> <td>84</td> <td rowspan="2">OND + DEX better than MCP + DEX </td> </tr> <tr> <td>MCP (10 mg) + DEX (10 mg)</td> <td>20</td> </tr> <tr> <td rowspan="2">Sykes<sup>5</sup> </td> <td rowspan="2">66 </td> <td rowspan="2">8 to 12.5 Gy (HBI, single fraction) </td> <td>OND (8 mg x 2 PO)</td> <td>94</td> <td rowspan="2">OND better than CLP + DEX </td> </tr> <tr> <td>CLP (25 mg x 3 PO) + DEX (6 mg x 3 PO)</td> <td>34</td> </tr> <tr> <td rowspan="2">Spitzer<sup>6</sup> </td> <td rowspan="2">34 </td> <td rowspan="2">TBI: 13.2 Gy in 11 fractions over 4 days </td> <td>OND (8 mg x 3/day PO)</td> <td>47</td> <td rowspan="2">No difference </td> </tr> <tr> <td>GRAN (2 mg x 1/day PO)</td> <td>61</td> </tr> </tbody></table></div><div class="graphic_footnotes">TBI: total body irradiation; IV: intravenously; OND: ondansetron; PO: orally; GRAN: granisetron; MCP: metoclopramide; DEX: dexamethasone; LOR: lorazepam; HBI: hemibody irradiation; CLP: chlorpromazine.<br/>* All patients received intravenous dexamethasone (8 mg) and phenobarbitone (60 mg/m<sup>2</sup>).</div><div class="graphic_reference">References:<br/><ol>
<li>Tiley C, Powles R, Catalano J, et al. Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation. Leuk Lymphoma 1992; 7:317.</li>
<li>Spitzer TR, Bryson JC, Cirenza E, et al. Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. J Clin Oncol 1994; 12:2432.</li>
<li>Prentice HG, Cunningham S, Gandhi L, et al. Granisetron in the prevention of irradiation-induced emesis. Bone Marrow Transplant 1995; 15:445.</li>
<li>Huang X, Guo N, Fan Y. [Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)]. Zhonghua Zhong Liu Za Zhi 1995; 17:64.</li>
<li>Sykes AJ, Kiltie AE, Stewart AL. Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. Support Care Cancer 1997; 5:500.</li>
<li>Spitzer TR, Friedman CJ, Bushnell W, et al. Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Transplant 2000; 26:203.</li></ol></div><div id="graphicVersion">Graphic 73445 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
